Moreover, PCSK9 inhibitors are indicated and provide new options for the treatment of hypercholesterolemia in adults with established atherosclerotic CVD (i.e., myocardial infarction, stroke, or peripheral arterial disease) to reduce CV risk by lowering LDL-C levels, as an adjunct to the maximum tolerated dose of a statin with or without other LLT or, alone or in combination with other LLT in statin-intolerant patients. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.